ArticleBMC medical imaging2026
An interpretable machine learning approach using nnU-Net-based radiomics for preoperative risk stratification of thymic epithelial tumors: a multicenter study.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThis study aimed to develop and validate an interpretable machine learning (ML) model based on nnU-Net automated segmentation and computed tomography (CT) radiomics for preoperative risk stratification in thymic epithelial tumors (TETs).
methodsIn this retrospective multicenter study, 764 patients with pathologically confirmed TETs were enrolled and divided into training, internal validation, and two external validation cohorts. An nnU-Net model was trained for automatic tumor segmentation, with performance assessed by the dice similarity coefficient (DSC). Radiomic features were extracted from the automated segmentations of venous-phase CT images, and least absolute shrinkage and selection operator (LASSO) regression was applied for feature selection. Predictive models, including radiomics-only, clinical-only, and a clinical-radiomics (combined) model, were constructed using five ML algorithms (RF, SVM, KNN, DT, and LR). Model performance was evaluated using the receiver operating characteristic (ROC) curve. Delong’s test was employed to compare these ML models and select the best-performing model as the final model. Calibration curve and decision curve analysis (DCA) were performed to assess clinical efficacy of the final model. The interpretability of the optimal model was elucidated using SHapley Additive exPlanations (SHAP).
resultsThe nnU-Net segmentation model achieved excellent performance, with a DSC of 0.979 on the test cohort. Compared to the other four combined models, the RF-based combined model demonstrated superior predictive efficacy, yielding area under the curve (AUC) values of 0.941 (training), 0.884 (internal validation), 0.867 (external validation 1), and 0.872 (external validation 2). The calibration curves indicated excellent agreement between the RF-based model’s predictions and actual outcomes, and furthermore, DCA confirmed its superior net benefit over baseline strategies across a wide range of thresholds. SHAP tool identified 11 radiomic features and 3 clinical features as the most influential features, providing transparency into the model’s decision-making process.
conclusionsThe nnU-Net framework enables accurate and efficient automatic segmentation of TETs. The proposed RF-based combined model, integrating clinical and radiomic features, provides a robust and interpretable tool for identifying the high-risk TETs, holding promise for supporting clinical decision-making towards personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.